Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Michael Yee
Pharma
Only $300K for Biogen's Aduhelm in Q3, far below consensus
Biogen revealed a stunningly low number—$300,000—in third-quarter sales for Aduhelm, its Alzheimer's treatment, which is steeped in controversy.
Kevin Dunleavy
Oct 20, 2021 10:23am
FibroGen admits to manipulating data for anemia drug roxadustat
Apr 7, 2021 9:50am
Analysts to Gilead CEO: What's your plan to monetize remdesivir?
Apr 30, 2020 8:28pm
Biogen investors have plenty to worry about, $5B buyback or no
Mar 26, 2019 10:41am
